Brief: Akebia Announces Establishment Of Rare Kidney Disease Pipeline
01/12/2025 13:21
Dec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIO AKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONS AKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026 Source text: ID:nGNXbsqDF1 Further company coverage: AKBA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule